QCG
INBX icon

Quadrant Capital Group’s Inhibrx INBX Stock Holding History

Quadrant Capital Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55
Closed -$3.7K – 1875
2026
Q1 		$3.7K Buy
+55
New +$4.08K ﹤0.01% 2414
2025
Q1 		– Sell
-146
Closed -$2.25K – 2799
2024
Q4 		$2.25K Sell
146
-25
-15% -$381 ﹤0.01% 2480
2024
Q3 		$2.68K Hold
171
– – ﹤0.01% 2446
2024
Q2 		$2.42K Buy
+171
New +$2.67K ﹤0.01% 2443

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quadrant Capital Group's INBX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 55 shares — an estimated $3.7K sold.

Quadrant Capital Group first reported a position in INBX in Q2 2024 and held it in 4 quarters. The position peaked at $3.7K in Q1 2026. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 55 Inhibrx shares in Q2 2026, an estimated $3.7K.
  • Quadrant Capital Group first reported a position in Inhibrx in Q2 2024 and held it in 4 quarters.
  • Quadrant Capital Group's Inhibrx position peaked at $3.7K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.